Cargando…

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice

Dengue virus (DENV) infection is a major global public health concern, and there is no effective vaccine for it. In this study, we describe the design and characterization of three nucleotide-modified mRNA vaccines (prME-mRNA, E80-mRNA, and NS1-mRNA) for DENV-2. Our results showed that vaccination w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Mengling, Sun, Jin, Li, Min, Jin, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452130/ https://www.ncbi.nlm.nih.gov/pubmed/32913878 http://dx.doi.org/10.1016/j.omtm.2020.07.013

Ejemplares similares

A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice
por: He, Lihong, et al.
Publicado: (2022)

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
por: Peng, Lei, et al.
Publicado: (2022)

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
por: Granados-Riveron, Javier T., et al.
Publicado: (2021)

An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates
por: Ripoll, Manon, et al.
Publicado: (2022)

A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice
por: Li, Dan, et al.
Publicado: (2023)

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
por: Baldeon Vaca, Gabriela, et al.
Publicado: (2023)

A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium
por: Kon, Edo, et al.
Publicado: (2023)

Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
por: Somiya, Masaharu, et al.
Publicado: (2021)

Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection
por: Chen, Tao, et al.
Publicado: (2022)

The effects of PEGylation on LNP based mRNA delivery to the eye
por: Ryals, Renee C., et al.
Publicado: (2020)

Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis
por: Zhang, Yizhuo, et al.
Publicado: (2023)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
por: Liu, Cong, et al.
Publicado: (2022)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
por: Moyles, Iain R., et al.
Publicado: (2023)

Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines
por: Yu, Xiaojuan, et al.
Publicado: (2023)

Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
por: Tsiambas, Evangelos, et al.
Publicado: (2021)

Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety
por: Vlatkovic, Irena
Publicado: (2021)

Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
por: Kiaie, Seyed Hossein, et al.
Publicado: (2022)

A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
por: Mao, Shanhong, et al.
Publicado: (2023)

Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
por: Naderi Sohi, Alireza, et al.
Publicado: (2021)

mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer
por: Qiu, Ke, et al.
Publicado: (2023)

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
por: Zhang, Lizhou, et al.
Publicado: (2023)

Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
por: Patel, Nisarg, et al.
Publicado: (2023)

Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
por: Maugeri, Marco, et al.
Publicado: (2019)

An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization
por: Hsu, Fu-Fei, et al.
Publicado: (2022)

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
por: Carter, Brandon, et al.
Publicado: (2023)

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
por: Kenjo, Eriya, et al.
Publicado: (2021)

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
por: Valentin, Antonio, et al.
Publicado: (2022)

mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
por: Bevers, Sanne, et al.
Publicado: (2022)

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2022)

Ionizable Lipids with Triazole Moiety from Click Reaction for LNP-Based mRNA Delivery
por: Wang, Yixiang, et al.
Publicado: (2023)

Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice against DENV2
por: Pinto, Paolla Beatriz A., et al.
Publicado: (2022)

Single-cell suspension preparation from murine organs following in vivo mRNA-LNP exposure
por: Ndeupen, Sonia, et al.
Publicado: (2022)

Prophylactic mRNA Vaccination against Allergy Confers Long-Term Memory Responses and Persistent Protection in Mice
por: Hattinger, E., et al.
Publicado: (2015)

Author Correction: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2023)

2342. Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model
por: England, Ross N, et al.
Publicado: (2023)

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
por: Hermosilla, Jesús, et al.
Publicado: (2023)

ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
por: Daly, Owen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gplb212lbed98v4267rce43830